Genomic and therapeutic landscape of non-muscle-invasive bladder cancer
Cooley, LF; Mclaughlin, KA; Meeks, JJ
HERO ID
6968151
Reference Type
Journal Article
Subtype
Review
Year
2020
Language
English
PMID
| HERO ID | 6968151 |
|---|---|
| Material Type | Review |
| In Press | No |
| Year | 2020 |
| Title | Genomic and therapeutic landscape of non-muscle-invasive bladder cancer |
| Authors | Cooley, LF; Mclaughlin, KA; Meeks, JJ |
| Journal | Urologic Clinics of North America |
| Volume | 47 |
| Issue | 1 |
| Page Numbers | 35-46 |
| Abstract | Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer. |
| Doi | 10.1016/j.ucl.2019.09.006 |
| Pmid | 31757298 |
| Wosid | WOS:000504951500006 |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |
| Language Text | English |
| Keyword | Bladder cancer; Mutation; Genomics; Immunotherapy; BCG |